2021 | Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis | EUROPEAN JOURNAL OF CANCER |
2020 | Scale-Up Evaluation of a Composite Tumor Marker Assay for the Early Detection of Renal Cell Carcinoma
| DIAGNOSTICS |
2020 | Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells
| FRONTIERS IN ONCOLOGY |
2020 | Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
| JOURNAL OF CLINICAL ONCOLOGY |
2020 | Cross-species oncogenic signatures of breast cancer in canine mammary tumors
| NATURE GENETICS |
2020 | Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells
| YONSEI MEDICAL JOURNAL |
2020 | Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE)-a randomized controlled trial | SUPPORTIVE CARE IN CANCER |
2020 | Unmet needs in the physical and daily living domain mediates the influence of symptom experience on the quality of life of gastric cancer patients | SUPPORTIVE CARE IN CANCER |
2019 | Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
| EUROPEAN UROLOGY ONCOLOGY |
2019 | Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
| FUTURE ONCOLOGY |
2019 | Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2019 | Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer | ONCOLOGIST |
2019 | Stability of symptom clusters and sentinel symptoms during the first two cycles of adjuvant chemotherapy | SUPPORTIVE CARE IN CANCER |
2019 | A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer | GASTRIC CANCER |
2019 | EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
| BMC CANCER |
2019 | Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma
| YONSEI MEDICAL JOURNAL |
2019 | Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer | EUROPEAN JOURNAL OF CANCER |
2019 | Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer | GASTRIC CANCER |
2019 | Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
| Journal for Immunotherapy of Cancer |
2019 | Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
| CANCER RESEARCH AND TREATMENT |
2019 | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
| CANCER RESEARCH AND TREATMENT |
2019 | Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients
| Cancer Research and Treatment |
2019 | Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma | Oncology |
2019 | Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
| Cancer Research and Treatment |
2019 | Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients
| Cancer Research and Treatment |
2019 | Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer | RADIOTHERAPY AND ONCOLOGY |
2019 | Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2019 | The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer.
| GASTRIC CANCER |
2019 | S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
| CANCER RESEARCH AND TREATMENT |
2018 | Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition
| CANCERS |
2018 | Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma | BRITISH JOURNAL OF CANCER |
2018 | Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
| BMC CANCER |
2018 | Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer
| JOURNAL OF CELLULAR AND MOLECULAR MEDICINE |
2018 | Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer | ANTICANCER RESEARCH |
2018 | Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial | CLINICAL CANCER RESEARCH |
2018 | CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer
| YONSEI MEDICAL JOURNAL |
2018 | BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
| INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
2018 | Reconsideration of sample size and power calculation for overall survival in cancer clinical trials
| CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS |
2018 | MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis. | JOURNAL OF SURGICAL ONCOLOGY |
2018 | Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions.
| CANCER RESEARCH AND TREATMENT |
2018 | Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG) | GASTRIC CANCER |
2018 | Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial | ANNALS OF SURGICAL ONCOLOGY |
2018 | A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy | AAPS JOURNAL |
2018 | The prognostic value of volume-based parameters using<sup>18</sup>F-FDG PET/CT in gastric cancer according to HER2 status | GASTRIC CANCER |
2018 | Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee.
| KOREAN JOURNAL OF INTERNAL MEDICINE |
2018 | Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor | INTERNATIONAL JOURNAL OF CANCER |
2018 | Rab25 augments cancer cell invasiveness through a beta1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin | EXPERIMENTAL AND MOLECULAR MEDICINE |
2018 | The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control | CANCER NURSING |
2018 | Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
| BMC CANCER |
2017 | PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
| ONCOTARGET |